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An Overview of this Value in Health
Special Issue
Few recent issues in drug development and health systems man-
agement have generated more commentary, and more contro-
versy, than health technology assessment (HTA). The keen
interest in HTA stems from the high stakes involved. For regard-
less of differences in deﬁnition and application, it is clear that
HTA brings together public and private interests in a process in
which there are potentially winners and losers, and the percep-
tion of outcome is highly contingent on each party’s point of
view. Critics charge that HTA has been used simply to restrict
access to new health-care technology, whereas advocates under-
score use of HTA to promote efﬁcient resource allocation and to
advance population-based health.
Any contemporary body of work on HTA needs to reconcile,
by deﬁnition, the relationship between HTA [a form of policy
research that examines short- and long-term consequences of
the application of a health-care technology] and evidence-based
medicine (EBM) [clinical evidence analysis for individual
decision-making practice guideline, and policy decision-
making]. Underlying these concepts is the demand for informa-
tion on the comparative effectiveness (CE) of health-care
interventions when used in actual practice. With this Value in
Health Special Issue, we seek to inform this ongoing debate on
the nature and role of HTA by bringing together leading acade-
micians and practitioners from around the world to offer their
perspectives on HTA in their country and to identify lessons
learned. In Article 2, “Health Technology Assessment and Evi-
dence Based Medicine: What Are We Talking About?” the rela-
tionship between HTA and EBM are presented as well as an
overview of HTA as a process. In Articles 3 to 7 (“Nasty or Nice?
A Perspective on the Use of Health Technology Assessment in the
United Kingdom”; “Health Technology Assessment in Canada:
20 Years Strong?”; Health Technology Assessment: A Perspective
from Germany”; “Health Technology Assessment: Reﬂections
from the Antipodes”; and “Health Technology Assessment in
Health-Care Decisions in the United States”), we asked contribu-
tors from the United Kingdom, Canada, Germany, Australia, and
the United States to describe the health-care organizations
involved in HTA, their processes, and the use of HTA in health-
care decisions of their respective countries, and to assess their
HTA processes across a range of important attributes: transpar-
ency of information and process, independence of, and partici-
pation in the assessment and appraisal, use of QALY thresholds,
methods to deal with uncertainty, and the role of “real-world”
data. We further asked contributors to elicit how HTA function
in practice care across a range of equity, efﬁciency and access
dimensions, effects on patient and provider choice and access,
effects on health-care budgets and health outcomes, and the role
of politics in the process. Some contributors addressed all of
these attributes and practical considerations, whereas others
only addressed attributes and practical considerations deemed
relevant in their country. Article 8—“Lessons for Health
Technology Assessment: It Is Not Only about the Evi-
dence”—emphasizes the similarity of country-speciﬁc HTA
systems and processes and presents future direction.
Although the country-speciﬁc HTA health organizations and
processes presented in this Special Issue may vary, we see emerg-
ing from these articles a set of common issues about the role of
HTA in society, its effects on public health and access to care, its
effects on innovation, and on the integrity and viability of pub-
licly ﬁnanced health care in general. We see HTA at the focal
point of an ongoing struggle across a range of countries attempt-
ing to come to terms with expanding expenditures for health
care, the availability of remarkable new innovations in health-
care technology, and constrained budgets. Although this Special
Issue will not resolve these concerns, it is hoped that by articu-
lating, comparing, and contrasting HTA systems and processes, it
enriches the discourse and helps build the common ground
needed to seek meaningful solutions; and that the lessons learned
can inform the development of HTA in societies confronting the
challenges of supporting economic growth and providing basic
health care.
The last article in this Special Issue, “Editorial: Pursing Efﬁ-
ciency: A Dead End for HTA?” is provided by a guest editor.
Guest editors are selected by the Value in Health editor-in-chief
to critique this Special Issue to ensure that a broad range of views
are expressed.
We hope that you will ﬁnd this Value in Health Special Issue
on HTA both informative and engaging as we grapple with the
HTA challenges ahead.
HealthTechnology Assessment, Evidence-Based
Medicine, and Comparative Effectiveness
Notable progress has been made recently in understanding the
similarities and differences between and within HTA and EBM
processes. Health technology assessment is a form of policy
research that examines short- and long-term consequences of the
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application of a health-care technology. Properties assessed
include evidence of safety, efﬁcacy, patient-reported outcomes,
real-world effectiveness, cost and cost-effectiveness as well as
social, legal, ethical, and political impacts [1]. As we shall see,
HTA is not a monolithic construct. A primary distinguishing
element among systems is the focus on the production of
evidence-based reports (e.g., by the Swedish Council on Technol-
ogy Assessment in Health Care Sweden’s Statens beredning för
medicinsk utvärdering [SBU]) and production of guidance deci-
sions linked to the use or reimbursement of health technologies
(e.g., National Institute for Clinical Excellence (NICE) in the UK
and Pharmaceutical Beneﬁts Advisory Committee (PBAC) in
Australia). Clearly economic concerns play a signiﬁcant role at
one end of the spectrum of HTA activities, but less so at the other.
EBM is the systematic collection and analysis of clinical evi-
dence to support medical decision-making [2]. David Eddy, a
contributor to this Special Issue, has helped us understand the
nuances within this EBM framework by distinguishing evidence-
based individual decision-making (EBID) from evidence-based
clinical guidelines (EBG), the latter intended to apply to groups
of patients deﬁned on the basis of clinical criteria, rather than to
individual patients as in EBID. EBG provides the systematic
review of research that individual health-care providers cannot
be expected to undertake, whereas EBID improves providers’
ability to apply guidelines to individual cases [3].
Comparative or relative effectiveness (CE), in turn, compares
interventions commonly used in actual practice in terms of their
medical outcomes, most desirably in real-world clinical settings
[4]. CE, HTA, and EBM are related by an integral component of
all three—clinical evidence. Despite this coalescence in deﬁni-
tional terms, controversy remains, even among practitioners,
particularly around the role of economic evaluation in HTA,
EBM, and CE, and we have endeavoured to provide some clarity
in this Special Issue in this critical area.
A Concise History of HTA
Although HTA processes may appear to be more advanced in
application outside of the United States, it is interesting to note
that technology assessment had a beginning in the US public
sector. It was during a meeting of the Congressional Committee
on Science and Astronautics in 1965 that Chairman Daddario
observed the need for policymakers to have information to facili-
tate the evaluation of the intended and unintended social, eco-
nomic, and legal impact of modern technology [5,6]. Borne out
of this was the Ofﬁce of Technology Assessment (OTA), an
agency that provided to Congress impartial assessments of tech-
nologies in medicine, telecommunications, agriculture, materials,
transportation, and defense that became the basis of many public
policies in the latter part of the 20th century [7]. The OTA model
was eventually adapted by Austria, Denmark, the European
Community, France, Germany, Great Britain, The Netherlands,
and Sweden [8], perhaps a harbinger of the interconnections
witnessed among HTAs today. Tellingly, OTA was disbanded in
1995 by withdrawal of congressional funding, perhaps because it
failed to navigate the political shoals and was tainted by the
perception that it had ventured too far into policymaking [9], the
prerogative of the Congress, and the Executive branch of the US
government.
Another relatively early model of HTA is SBU, which was
established in 1987 in Sweden’s Government Ofﬁce, loosely
modelled after the US OTA [10]. In 1992, SBU became an
independent, public body with the same remit from the
government—to provide unbiased scientiﬁc technology assess-
ments of health-care interventions for health-care decision-
makers as well as patients. Sweden’s SBU both provides reports
to support health-care decisions aimed at efﬁcient allocation of
Sweden’s health-care resources, and is also active in contributing
to the global development of HTA. For example, the SBU was
involved in the development of the International Network of
Agencies for Health Technology Assessment (INAHTA) and a
scientiﬁc journal, International Journal of Technology Assess-
ment in Health Care [11].
In Australia, the PBAC, a government committee of medical
experts who reviews industry submissions and recommends drugs
to be subsidized by the Australian Pharmaceutical Beneﬁts Scheme
(PBS), could also be viewed as having one of the earlier versions of
HTA [12]. Although the PBAC/PBS had been in existence formore
than 60 years, it was in 1992 that Australia unveiled its ﬁrst,
formal guidelines for pharmaceutical reimbursement [13].
With the soaring cost of health care in the late 1980’s, we saw
a resurgence of interest in HTA across the globe. In Canada,
it started in the Quebec Province in 1988 with the Conseil
d’évaluation des technologies de la santé (CETS) and in 2000 was
renamed to Agence d’évaluation des technologies et des modes
d’intervention en santé (AETMIS) with the mandate to evaluate
the safety and efﬁciency of various health-care interventions [14].
At the national level, Canadian Coordinating Ofﬁce for Health
Technology Assessment (CCOHTA) was formed in 1989 to
conduct effectiveness reviews for medical devices and shortly
thereafter added pharmaceuticals [15]. In 1994, CCOHTA pub-
lished Canada’s ﬁrst set of national guidelines for the economic
evaluation of pharmaceuticals that grew out of a 1993 Canadian
Collaborative Workshop on Pharmacoeconomics attended by
international experts and representatives of Canada’s provincial,
territorial, and federal health-care systems [15]. Over the years
the scope of this body has been transformed. To reﬂect the larger
mandate of promoting effective utilization of technology at
the federal, provincial, and territorial level, CCOHTA was
rebranded in 2006 as the Canadian Agency for Drugs and Tech-
nologies in Health (CADTH) [15]. As part of the heath care
reform in 2003, a Common Drug Review (CDR) process was
implemented by CCOHTA to increase the consistency and
quality of the drug review process across the provinces. The
national Canadian Expert Drug Advisory Committee (CEDAC)
was established as part of the CDR to provide independent
reviews of the manufacturer submissions and to make recom-
mendations to provincial health-care systems for formulary
listing. Canada’s national buying power coupled with the use of
HTA has enabled it to negotiate more aggressive pricing than its
neighbor, the United States.
In 1999, when the UK introduced the National Institute for
Clinical Excellence (NICE), which subsequently became the
National Institute for Health and Clinical Excellence, to provide
guidance on new technologies and treatment of diseases, it sig-
niﬁcantly contributed to the globalization of HTA. NICE’s clear
remit to establish a transparent review process to determine how
well the treatment work clinically in relation to how much it will
cost the National Health Service (NHS)—does it represent value
for money—continue to garner much interest across the globe.
The appraisals are conducted by an independent Technology
Appraisal Committee with membership from key stakeholders:
NHS, patient advocacy groups, academia, and the medical tech-
nology industries [16]. Although NICE recommendations are not
statutorial mandates, NHS is obligated to implement the recom-
mendations thus conferring signiﬁcant weight to NICE reviews.
The impact of NICE’s recommendations are also far reaching
because the reviews are publicly available. A positive or negative
decision by NICE can have market implications beyond the UK.
For example, “hit” statistics from the NICE website indicate
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wide usage by North American health-care decision-makers
(Andrew Dillon, personal communication, Molndal, Sweden,
November 2005).
Despite the disappearance of the OTA, the United States has
also experimented with in HTA since the 1990s. With the decen-
tralized US public and private health-care systems, a handful of
EBM or HTA-like bodies support formulary decision-making.
Health-care plans can commission or purchase HTAs conducted
by third party entities such as the Blue Cross Blue Shield Asso-
ciation Technology Evaluation Center (TEC) and the Emergency
Care Research Institute (ECRI) [17,18]. The State of Oregon’s
Drug Effectiveness Review Project (DERP) is probably the most
well recognized body in the United States applying principles of
EBM to formulary decision-making in the public sector. DERP
has gained much national attention for limiting its reviews to a
restricted range of evidence typically randomized clinical trials
and applying its conclusions in a policy environment more
suited to HTA. DERP is currently sponsored by many US State
Medicaid programs and Canada’s CADTH. In addition to efforts
by DERP, BCBS TEC, and ECRI in the United States, a formulary
dossier submission format endorsed by the Academy of Managed
Care Pharmacy has been adopted in whole or in part by many
managed care plans. This has allowed health plans to proactively
request information and to also standardize the analysis and
presentation of that clinical and economic information across the
medical technology companies to facilitate the formulary evalua-
tion process [19].
One of the newest HTA models was introduced by Germany
during its 2004 health-care reform, focused on an independent
body named the Institute for Quality and Efﬁciency in Health
Care (Institut für Qualität und Wirtschaftlichkeit im Gesund-
heitswesen [IQWiG]) [20]. IQWiG, similar to NICE, conducts
studies of pharmaceuticals, surgical procedures, clinical practice
guidelines, and disease management programs. These evaluations
are usually commissioned by Germany’s Federal Joint Commis-
sion, Gemeinsamer Bundesausschuss (G-BA), or the Federal Min-
istry of Health. Most products are automatically reimbursed
once approved with a reference price system that placed limits on
the level of reimbursement for off-patent drugs and patented
drugs considered to be “me-too” products. Unless a medicine can
demonstrate clear innovation or therapeutic superiority over
existing therapies, reference pricing is applied by the G-BA. Cur-
rently, Germany is undergoing another health-care reform effort
with one of its goals being “to further increase efﬁciency in
the prescription of drugs, especially of the very expensive ones”
[21].
The Challenge of HTA International
Comparisons
Differences in culture, history, politics, health-care ﬁnancing, and
the underlying rationale for undertaking HTA in general, all have
had important effects on the makeup and function of HTA in
each country. To this point, a recent review conducted by the
UK’s Ofﬁce of Health Economics revealed few systematic within-
country patterns in HTA conﬁguration and behaviour across any
of six dimensions measured [22]. The refrain, if you have seen
one HTA system, you have seen them all, simply doesn’t apply.
Rather, in undertaking this comparison we were repeatedly
admonished that if you have seen one HTA system, you have seen
one HTA system. Such heterogeneity among HTA systems could
confound an unstructured approach to eliciting common
“lessons learned.” Many contributors to this Special Issue found
this charge quite difﬁcult to complete in any truly comprehensive
way because of the paucity of studies on the actual outcomes of
HTA. Thus, if this Special Issue makes any lasting contribution,
it is hoped that its call for more research on the societal effects of
HTA is heeded.
In any attempt to make international comparisons, one is
challenged by the relevance of each case study to any other. Other
cross-national comparisons have foundered on the rocks of gen-
eralizability. Nevertheless, we hope you see, as we do, the impor-
tant challenges and opportunities inherent in HTA systems
globally. As societies grapple with the role of HTA in health care
it is likely that we will see some convergence in methods, or at
least further collaboration. It is our hope that any convergence in
HTA systems is accomplished on the basis of sound program
evaluation, with consideration of societal outcomes, and accom-
modation and reconciliation as possible of all relevant points of
view and involving all relevant stakeholders.
The Impact of HTA Systems on Societal
Health Outcomes
For a process of such critical importance to all
stakeholders—governments, patients, providers, payers, and
medical technology ﬁrms alike—one would expect a large and
growing body of research on its structure, its process, and espe-
cially, its outcomes. However, a review of the existing literature
on HTA reveals a startling lack of depth, particularly on the
impact HTA has had on health-care budgets, efﬁciency, and on
societal health outcomes. Indeed one commentary noted that
whereas the previous 10 years have been well-spent on building
the HTA/EBM infrastructure and evidence base, the next 10
should focus on the outcomes [23].
The vast majority of the research on HTA has focused on the
conﬁguration of respective systems, and on the process, such as
identifying the determinants of a positive HTA review. The focus
on structure and process over national and societal outcomes is
not surprising given the relative ease of evaluating structure and
process, and the challenges of assessing outcomes in ecological
studies. Beyond the methodological difﬁculties, though, one may
detect a lower priority level accorded outcomes among govern-
ments wholly absorbed with building HTA infrastructure, and
simultaneously trying to avoid the political pitfalls related to the
perception that HTA is simply the rationing of health care dis-
guised as rigorous policy analysis. In addition to the paucity of
research on outcomes, even among the existing studies, the vast
majority are focused on NICE, which is not surprising given that
NICE is among the most highly transparent and visible HTA
organizations. Clearly, research on the broader array of HTA
systems is needed. In contrast, there has been a considerable
amount of research on the impact of EBM, especially evidenced-
based clinical guidelines [24,25], though Homans et al. found
that the research into the economic impact of clinical practice
guidelines was of poor quality [26].
Given the limitations noted, what can the literature tell us
about the impact of HTA? In terms of structure, although there
is wide variation among systems, a recent model holds that
structural patterns among systems are discernable, with primary
differences deriving from the policy implementation level (e.g.,
policy objectives of the system, legal status, and its relationships
with stakeholders) and the individual technology decision level
(e.g., assessment processes, how decisions are made, and how
they are implemented) [27]. Differences along these axes likely
have important implications for scope of the HTA approach,
inclusiveness of the process, implementation of recommenda-
tions, resistance to political inﬂuences and outcomes [28].
The impact of HTA on setting health-care priorities has also
been studied [28–31]. Although HTA has inﬂuenced priority-
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setting in health care in some systems, observers seem to agree
that the impact on priority setting has been modest at best [31].
The difﬁculty HTA has faced in incorporating political and social
value perspectives is cited as one key barrier. Similarly, HTA’s
traditional focus on the health service level versus the public
health level is yet another barrier. Although HTA can inform
health-care priority setting, in practice HTAs have, broadly
speaking, failed to deliver in this area, perhaps because of the
limits imposed by their level of policy implementation noted
earlier.
The remaining area of inquiry in the existing literature is on
aspects of the assessment and appraisal process itself, again with
a distinct focus on the NICE experience [32–34]. A quantitative
analysis of the determinants of NICE decisions revealed some
interesting but hardly surprising patterns. For example, NICE
dossiers containing more supportive clinical trials and lower,
more favorable cost-effectiveness ratios were more likely to
receive a positive review [31]. Similarly, a review of 86 NICE
guidances found that nearly two-thirds of NICE’s negative
appraisals were associated with lack of evidence and high cost-
effectiveness ratios [33]. Studies examining cost-effectiveness
thresholds have generally supported the £30 000 cost/QALY
cutoff for NICE acceptability, with some variation for products
in high-need areas [31,33].
As HTA systems are reﬁned and indeed exported to countries
developing HTA system infrastructure, more research on the
structure, process, and outcome of HTA systems is warranted.
The Lessons of HTA and EBM: Challenges and
Opportunities of the Future
Throughout this Special Issue, the various commentaries and case
studies of HTA and EBM from around the world conﬁrm that
ample opportunity for continued development and improvement
of HTA and EBM exist and that no one model will be universally
applicable or even acceptable to all societies. Assessments face a
number of challenges, not the least of which is the limitation of
existing and emerging methodologies and data sources. Improv-
ing the assessment process, improving methods and data, and
growing the cadre of researchers and ofﬁcials able to do and
interpret HTA, respectively, will enable societies to expand their
ability to conduct and use HTA. However, these scientiﬁc
advances can succeed in expanding the value of HTA only if the
societal or political dimension is also addressed uniquely for each
society. To be comprehensive and reﬂecting the full value of
health-care technologies, the HTA process—regardless of the
country or health-care system—should combine assessments of
clinical effectiveness, societal values, budget impact and economic
efﬁciency, as well as ethical judgments pertinent to the relevant
population. The scientiﬁc methods and the data to accomplish the
initial aspects of these assessments, as well as the process overall
that uses these methods and data, have to be transparent,
credible, and consistently applied.
Investments are needed to increase the availability of appro-
priate data to support the assessments on an ongoing basis.
Further, these data must be accessible to multiple stakeholders to
ensure transparency and promote trust among the key stakehold-
ers. As well, the process that brings together the researchers, the
methods and the data must be open and transparent, fostering
the public trust among stakeholders that is a necessary precon-
dition to acceptance of HTA assessments.
Moving forward it is useful to recall that the ﬁeld of outcomes
research in the United States was promoted in the late 1980s and
early 1990s by the Federal Government, which identiﬁed a need
for disease-speciﬁc Patient Outcomes Research Teams (PORTs)
to evaluate the clinical, economic and patient-reported outcomes
of diseases and the differential aspects of alternative diagnostic
and therapeutic modalities. In fact, the PORTs were a mechanism
to accomplish multiple goals that are equally applicable here.
First was the need for methods development—e.g., meta-
analysis, decision- and cost-effectiveness analysis, real-world
data analysis (both retrospectively using claims and other data,
as well as prospectively), and patient outcomes and survey
research. Second was the need to train more skilled researchers.
The lessons of HTA worldwide support these twin needs to
continue to improve the scientiﬁc methods that comprise HTA.
Inasmuch as no single method can accomplish all that is needed,
multiple methods need to continue to be brought to bear. This
will require societies, and typically both public and private enti-
ties, to invest in both the advancement of methods and in the
training of more individuals who can and will either conduct
HTA, or consider it in their health-care policymaking or health-
care delivery decisions. Just as we recall that the OTA was
disbanded by the US Congress because it ran afoul of key con-
stituencies, so the predecessor of the Agency for Healthcare
Research and Quality—the Agency for Health-care Policy and
Research, which administered the PORTs—was almost similarly
hobbled politically because its ﬁndings were opposed by inﬂuen-
tial sectors of the medical provider community.
HTA is not merely the application of good scientiﬁc evalua-
tion methods—it must be that to be viable or successful.
However, to be successfully implemented, the HTA process must
consider the social or ethical context. That is, HTA must be
applied with open and transparent consideration of the common
good—as understood by the public and industry alike. As has
been shown by NICE, CADTH, and others, HTA assessments
must be done in a transparent manner with respect to: 1) the
choice of technologies or services assessed; 2) the conduct of the
assessments; and 3) the application of the assessment results to
decisions related to access and reimbursement.
Moreover, any investment in the scientiﬁc progress of HTA
must be accompanied by investment in engaging the public
directly. The social and ethical discussions must be accorded
special attention. Transparency of the process is critical. Focused
engagement of and active participation by all stakeholders is even
more critical. The involvement of health-care professionals,
patient advocacy groups, medical technology ﬁrms, and other
inﬂuential bodies will be challenging and at certain times con-
tentious. However without positive social interaction along with
the advancement of science, HTA will not be as effective as
proponents claim in improving the effectiveness and efﬁciency of
health care. Recall that although OTA was an important early
developer and proponent of HTA, and was scientiﬁcally astute, it
was eventually abolished in part because it and its Congressional
supporters were not sufﬁciently responsive politically. In summa-
tion, to succeed, HTA will require investments of time, personnel
and ﬁnancial resources, and attention to scientiﬁc, social and
political issues. However, for HTA to succeed optimally, its
acceptance by multiple key stakeholders will be necessary. This
will require engagement of health-care professionals, patient
advocacy groups, and medical technology ﬁrms, facilitated
by an HTA process that is recognized as open, transparent and
consistent.
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